Literature DB >> 31001628

Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis.

Ibrahim M Sayed1,2, Lieven Verhoye1, Claire Montpellier3,4, Florence Abravanel5,6,7, Jacques Izopet5,6,7, Laurence Cocquerel3,4, Philip Meuleman1.   

Abstract

BACKGROUND: Hepatitis E virus infection (HEV) is an emerging problem in developed countries. Diagnosis of HEV infection is based on the detection of HEV-specific antibodies, viral RNA, and/or antigen (Ag). Humanized mice were previously reported as a model for the study of HEV infection, but published data were focused on the quantification of viral RNA. However, the kinetics of HEV Ag expression during infection remains poorly understood.
METHODS: Plasma specimens and suspensions of fecal specimens from HEV-infected and ribavirin-treated humanized mice were analyzed using HEV antigen-specific enzyme-linked immunosorbent assay, reverse transcription-quantitative polymerase chain reaction analysis, density gradient analysis, and Western blotting. RESULT: Open reading frame 2 (ORF2) Ag was detected in both plasma and stool from HEV-infected mice, and levels increased over time. Contrary to HEV RNA, ORF2 Ag levels were higher in mouse plasma than in stool. Interestingly, ORF2 was detected in plasma from mice that tested negative for HEV RNA in plasma but positive for HEV RNA in stool and was detected after viral clearance in mice that were treated with ribavirin. Plasma density gradient analysis revealed the presence of the noninfectious glycosylated form of ORF2.
CONCLUSION: ORF2 Ag can be used as a marker of active HEV infection and for assessment of the effect of antiviral therapy, especially when fecal samples are not available or molecular diagnostic tests are not accessible.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HEV Ag; ORF2; diagnosis; humanized mice; ribavirin therapy

Year:  2019        PMID: 31001628     DOI: 10.1093/infdis/jiz171

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  5 in total

1.  Evaluation of hepatitis E antigen kinetics and its diagnostic utility for prediction of the outcomes of hepatitis E virus genotype 1 infection.

Authors:  Mohamed A El-Mokhtar; Haidi Karam-Allah Ramadan; Muhamad R Abdel Hameed; Ayat M Kamel; Sahar A Mandour; Maha Ali; Mohamed A Y Abdel-Malek; Doaa M Abd El-Kareem; Sara Adel; Eman H Salama; Khaled Abo Bakr Khalaf; Ibrahim M Sayed
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

2.  Evidence of the Extrahepatic Replication of Hepatitis E Virus in Human Endometrial Stromal Cells.

Authors:  Mohamed A El-Mokhtar; Essam R Othman; Maha Y Khashbah; Ali Ismael; Mohamed Aa Ghaliony; Mohamed Ismail Seddik; Ibrahim M Sayed
Journal:  Pathogens       Date:  2020-04-17

3.  Clinical Outcomes and Prevalence of Hepatitis E Virus (HEV) Among Non-A-C Hepatitis Patients in Egypt.

Authors:  Ibrahim M Sayed; Mohamed A El-Mokhtar; Mahmoud Abdel Rahman Mahmoud; Amal A Elkhawaga; Shereen Gaber; Nermien H Seddek; Lobna Abdel-Wahid; Ahmed M Ashmawy; Enas Ahmed Reda Alkareemy
Journal:  Infect Drug Resist       Date:  2021-01-12       Impact factor: 4.003

4.  Characterization of Chronic Hepatitis E Virus Infection in Immunocompetent Rabbits.

Authors:  Chunnan Liang; Chenyan Zhao; Tianlong Liu; Bo Liu; Zhiguo Liu; Huili Huang; Wei Liu; Minghai Zhao; Nan Xu; Qiong Lu; Jianhui Nie; Li Zhang; Weijin Huang; Ruiping She; Youchun Wang
Journal:  Viruses       Date:  2022-06-09       Impact factor: 5.818

5.  Hepatitis E Virus Persistence and/or Replication in the Peripheral Blood Mononuclear Cells of Acute HEV-Infected Patients.

Authors:  Ibrahim M Sayed; Zeinab A Abd Elhameed; Doaa M Abd El-Kareem; Mohamed A Y Abdel-Malek; Mohamed E Ali; Maggie A Ibrahim; Ayat Abdel-Rahman Sayed; Khaled Abo Bakr Khalaf; Lobna Abdel-Wahid; Mohamed A El-Mokhtar
Journal:  Front Microbiol       Date:  2021-07-16       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.